-
Mizuho's Valeant Calculation: DCF + SOTP = $18/Share
Monday, March 21, 2016 - 10:54am | 315Read More...News of Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s downgrade at Mizuho is circling Wall Street on Monday, largely because of the firm's Street-low price target of $18 per share. How did Mizuho get to this valuation? Let's take a look. According to analysis from Irina Koffler,...
-
Valeant Investors Should Wait And See What Happens, Scotiabank Says
Monday, March 21, 2016 - 10:45am | 180Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors should take a wait and see approach, an analyst said on Monday. According to Scotiabank's Alan Ridgeway, anyone on the fence should "wait and see how the next few months play out." Ridgeway holds a Sector Perform and a $42 price target on the...
-
Tsao: Valeant Has $76 Upside But $12 Downside
Monday, March 21, 2016 - 10:23am | 370Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are having a good Monday after the company announced it's searching for a new CEO and that hedge fund activist Bill Ackman will join the board. Earlier in the morning, Barclays analyst Douglas Tsao downgraded the stock with a $34 price...
-
Andrew Left Vs. Mallinckrodt CEO Debate Live On CNBC: What You Missed
Tuesday, March 15, 2016 - 6:07pm | 363Read More...Mallinckrodt PLC (NYSE: MNK) shares sold off 14 percent on Tuesday after Citron's Andrew Left compared the company -- again -- to Valeant Pharmaceuticals Intl Inc (NYSE: VRX). "Mkt. is starting to realize that $MNK equal risk to $VRX," Left tweeted around 2pm ET. Valeant finished...
-
Amsellem: Valeant Has No Floor
Tuesday, March 15, 2016 - 4:27pm | 324Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) finished Tuesday down 51 percent. The stock is down even further since Probes Reporter first reported the company was facing an undisclosed SEC probe on February 29. David Amsellem of Piper Jaffray recently told CNBC why he's Underweight Valeant...
-
Valeant Corrects Guidance Error Hours After Earnings Release: What Happened?
Tuesday, March 15, 2016 - 11:45am | 277Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) continues to fall more than an hour after the company issued a correction to its Tuesday morning earnings release. Upon reporting, Valeant initially said it expected adjusted EBITDA to be between $6.2 billion and $6.6 billion for the next four quarters...
-
Canadian Authorities Could Be Looking Into Valeant
Tuesday, March 1, 2016 - 12:56pm | 906Read More...Regulators' involvement with Valeant Pharmaceuticals Intl Inc (NYSE: VRX) could last quite a while, according to John P. Gavin, CFA, founder and CEO of Probes Reporter, the research firm that broke Monday's news of an undisclosed SEC investigation into the Canadian pharmaceuticals company...
-
New Data Confirms Valeant's Undisclosed SEC Investigation
Monday, February 29, 2016 - 12:44pm | 237Read More...Probes Reporter, an independent publisher of investment research that focuses on public company interactions with the SEC, said last week that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is likely facing a new SEC investigation that hasn't been disclosed to the investment community. Probes...
-
Valeant Withdraws Prior Guidance, Announces CEO Mike Pearson Will Return To Work Immediately Following Pneumonia Scare
Monday, February 29, 2016 - 8:35am | 250Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged more than 8 percent early Monday morning after the company issued a business update over the weekend. Valeant confirmed that Michael Pearson will resume his role as CEO, effective immediately. The executive was hospitalized...
-
Valeant Has Risk Of New Undisclosed SEC Probe, Report Says
Tuesday, February 23, 2016 - 10:07am | 293Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is facing an undisclosed SEC investigation, according to a report by Probes Reporter, an independent publisher of investment research that focuses on public company interactions with the SEC, Probes Reporter noted that it received a letter dated...
-
Valeant Gets Closer To Left's $50 Target After New Accounting Fears
Monday, February 22, 2016 - 9:59pm | 379Read More...Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares plunged nearly 9 percent in Monday's after-hours trading session following word the company may have to restate financial results, before recovering slightly. The potential restatement, according to sources, would come on the heels of a...
-
UPDATE: Valeant Plunges 7% After Bearish Wells Fargo Report
Friday, February 19, 2016 - 12:27pm | 252Read More...Valeant's stock has reacted to Wells Fargo's latest analysis of the company, seen below on Benzinga Pro. Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) opened for trading on Friday at $90.48 and moved lower throughout the morning trading session. After nearly 2 full hours of...
-
Valeant Trends Down Following Oversight Committee Release Of Docs
Tuesday, February 2, 2016 - 1:51pm | 209Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by more than 3 percent early Tuesday afternoon following the release of a memorandum from the U.S. Committee on Oversight and Government Reform. The memorandum, titled "Documents Obtained by Committee from Valeant...
-
Express Scripts Calls Out Valeant, Says It's 'Holding Pharmaceutical Manufacturers Accountable For Excessive Price Hikes'
Friday, January 29, 2016 - 2:03pm | 363Read More...Express Scripts Holding Company (NASDAQ: ESRX), the largest pharmacy benefit management organization in the U.S., announced on Friday it has decided to exclude Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s Glumetza from its formulary. Express Scripts noted that throughout Valeant...
-
Martin Shkreli Avoids Congressional Drug Price Hearings; Valeant Interim CEO Plans To Appear
Thursday, January 21, 2016 - 12:00pm | 210Read More...Former Turing Pharmaceuticals CEO Martin Shrkeli has refused to comply with a subpoena to testify in front of a Senate panel, which convenes next week to discuss drug prices, ArsTechnica reports. It's likely Shkreli also won't appear before a House committee investigation, given his...
